Haga A, et al. - Researchers undertook a comparative exploration of the 1-year outcomes of treat-and-extend (TAE) and every-other-month (2M) regimens with intravitreal aflibercept in Japanese wet age-related macular degeneration (AMD) patients. They concluded that both the treat-and-extend (TAE) regimen with aflibercept and 2M regimen improved the best-corrected visual acuity (BCVA) and central retinal thickness (CRT) to the same extent, with a reduced number of injections.